McKesson Corporation (NYSE:MCK) was trading at around $916 on October 5, up 1.53% on the day and 21.72% over twelve months.
The company collected $410.98 billion in revenue and kept $4.59 billion, a net margin of 1.12%. Its book value per share is negative $36.55. A business with almost no margin and no equity is worth $94.37 billion, and the reason is the size of the first number.
READ ALSO: MongoDB (MDB) vs Snowflake (SNOW): Which is a Better Stock to Buy?
A Penny on Every Dollar, Four Hundred Billion Times:
McKesson buys drugs from manufacturers and delivers them to pharmacies. It does not make them, price them, or prescribe them. That is why the spread is thin by design. The manufacturer sets the price, and the pharmacy knows the cost, so there is no room to charge more.
What turns it into a business is the size of the base. One point one two percent of $410.98 billion is $4.59 billion, earned on a fixed network that does not get more expensive as volume rises. The structure is unusually clean. Only twenty-three basis points separate the 1.35% operating margin from the 1.12% net margin, so almost nothing sits below the operating line.
Cash confirms it, at $6.8 billion free against $6.85 billion operating, with no capital spending gap. That cash retired the equity. A business this asset-light can buy back stock year after year, and 116.59 million shares now carry $410.98 billion of revenue.
DON’T MISS: What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
Why a Thin Margin Is Not the Same as a Weak One:
The margin that looks like a weakness is closer to a barrier. A competitor would have to build the warehouses, the network, and the approvals, then accept roughly one percent on whatever it won. Nobody does that, which is why three companies move most of the drugs in the United States.
The cost of that protection is how little tolerance it leaves. Earnings fell 21.70% last quarter while revenue grew 7.70%. That combination is the whole risk in one line. Revenue rising while profit falls by a fifth means the spread per package moved by a few basis points, and at a 1.12% margin a few basis points is the year.
The borrowing is modest against that, at $11.8 billion with $6.8 billion of annual free cash flow behind it. Earning a penny on the dollar is a model very few businesses could survive. Ten stocks positioned for high returns in 2026 are named here.
The Valuation Case:
McKesson traded near $916 on October 5 and is worth $94.37 billion. Sustainability is unusually good. Drugs have to get from factories to pharmacies, and the margin is too thin to attract anyone new.
On price, the ratios look strange until you remember the margin. Price to sales is 0.26, so the market pays twenty six cents for every dollar billed, which says nothing about whether the shares are cheap. On earnings the stock is ordinary, at 23.62 times trailing and 19.72 times forward.
A beta of 0.30 reflects demand that does not care about the economy. The dividend yields 0.42% because almost all the cash stays inside for buybacks. For companies that send it out instead, see this year’s best payers.
Conclusion:
The thin margin is the moat rather than the flaw. Nobody builds a national drug network to earn 1.12%, which is why three companies share the work. Free cash flow of $6.8 billion against $4.59 billion of profit shows the model collects what it books. However, last quarter revenue grew 7.70% while earnings fell 21.70%, which is what a few basis points of spread does at this margin. There is no equity left to absorb it. The number to watch is the operating margin, because 1.35% is the entire buffer.
Market Sentiment:
McKesson Corporation was held by 77 hedge funds with a combined stake value of about $4.33 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 73 hedge fund holders with a cumulative investment value of around $3.93 billion in the previous quarter.
READ NEXT: MongoDB (MDB) vs Snowflake (SNOW): Which is a Better Stock to Buy? and What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
This article is originally published at Insider Monkey.
